0001654954-21-006610.txt : 20210604 0001654954-21-006610.hdr.sgml : 20210604 20210604151758 ACCESSION NUMBER: 0001654954-21-006610 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210604 DATE AS OF CHANGE: 20210604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASO Corp CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 21996225 BUSINESS ADDRESS: STREET 1: 137 COMMERCIAL STREET, STE. 200 CITY: PLAINVIEW STATE: NY ZIP: 11803 BUSINESS PHONE: 516-997-4600 MAIL ADDRESS: STREET 1: 137 COMMERCIAL STREET, STE. 200 CITY: PLAINVIEW STATE: NY ZIP: 11803 FORMER COMPANY: FORMER CONFORMED NAME: VASOMEDICAL, INC DATE OF NAME CHANGE: 20120606 FORMER COMPANY: FORMER CONFORMED NAME: VASOMEDICAL INC DATE OF NAME CHANGE: 19950517 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 10-Q 1 vaso_10q.htm FORM 10-Q vaso_10q
5/27/2021 20:42 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 10-Q
 
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended March 31, 2021
 
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _______________ to ______________
 
Commission File Number: 0-18105
 
VASO CORPORATION
 
(Exact name of registrant as specified in its charter)
 

 Delaware
 
 11-2871434
 (State or other jurisdiction of incorporation or organization)
 
 (IRS Employer Identification Number)
 
137 Commercial St., Suite 200, Plainview, New York 11803
 
(Address of principal executive offices)
 
Registrant’s Telephone Number  (516) 997-4600
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes [X]No [ ]
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes [X] No [ ]
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
 
Large Accelerated Filer [ ] Accelerated Filer [ ] Non-Accelerated Filer [X] Smaller Reporting Company [X]
Emerging Growth Company [ ]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]
 
Securities registered pursuant to Section 12 (b) of the Act: None
 
Number of Shares Outstanding of Common Stock, $.001 Par Value, at June 2, 2021– 175,127,878

 

 
  
Vaso Corporation and Subsidiaries
 
INDEX
 
 
 

 

PART I – FINANCIAL INFORMATION
 
ITEM 1 - FINANCIAL STATEMENTS
 
Vaso Corporation and Subsidiaries
 
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
 
 
 
March 31,
2021
 
 
December 31,
2020
 
 
 
(unaudited)
 
 
 
 
ASSETS
 
 
 
 
 
 
CURRENT ASSETS
 
 
 
 
 
 
Cash and cash equivalents
 $9,432 
 $6,819 
Short-term investments
  763 
  766 
Accounts and other receivables, net of an allowance for doubtful
    
    
accounts and commission adjustments of $4,510 at March 31, 2021
    
    
and $4,208 at December 31, 2020
  4,532 
  9,776 
Receivables due from related parties
  18 
  18 
Inventories
  1,147 
  1,384 
Deferred commission expense
  2,512 
  2,354 
Prepaid expenses and other current assets
  1,064 
  1,151 
 Total current assets
  19,468 
  22,268 
 
    
    
PROPERTY AND EQUIPMENT, net of accumulated depreciation of
    
    
$9,214 at March 31, 2021 and $8,833 at December 31, 2020
  3,533 
  3,885 
OPERATING LEASE RIGHT OF USE ASSETS
  968 
  1,009 
GOODWILL
  15,683 
  15,688 
INTANGIBLES, net
  3,763 
  3,949 
OTHER ASSETS, net
  2,010 
  2,190 
INVESTMENT IN EECP GLOBAL
  1,129 
  1,116 
DEFERRED TAX ASSETS, net
  271 
  271 
Total assets
 $46,825 
 $50,376 
 
    
    
LIABILITIES AND STOCKHOLDERS' EQUITY
    
    
CURRENT LIABILITIES
    
    
Accounts payable
 $6,114 
 $6,285 
Accrued commissions
  116 
  1,474 
Accrued expenses and other liabilities
  5,818 
  4,867 
Finance lease liabilities - current
  180 
  190 
Operating lease liabilities - current
  602 
  540 
Sales tax payable
  544 
  621 
Deferred revenue - current portion
  12,387 
  11,516 
Notes payable - current portion
  3,972 
  5,970 
Due to related party
  108 
  236 
Total current liabilities
  29,841 
  31,699 
 
    
    
LONG-TERM LIABILITIES
    
    
Notes payable, net of current portion
  5,050 
  5,779 
Finance lease liabilities, net of current portion
  183 
  246 
Operating lease liabilities, net of current portion
  366 
  469 
Deferred revenue, net of current portion
  6,097 
  6,188 
Other long-term liabilities
  858 
  910 
Total long-term liabilities
  12,554 
  13,592 
 
    
    
COMMITMENTS AND CONTINGENCIES (NOTE N)
    
    
 
    
    
STOCKHOLDERS' EQUITY
    
    
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares
    
    
 issued and outstanding at March 31, 2021 and December 31, 2020
  - 
  - 
Common stock, $.001 par value; 250,000,000 shares authorized;
    
    
185,244,299 shares issued at March 31, 2021 and December 31, 2020;
    
    
174,936,212 shares outstanding at March 31, 2021 and December 31, 2020
  185 
  185 
Additional paid-in capital
  63,895 
  63,886 
Accumulated deficit
  (57,645)
  (57,002)
Accumulated other comprehensive income (loss)
  (5)
  16 
Treasury stock, at cost, 10,308,087 shares at March 31, 2021 and December 31, 2020
  (2,000)
  (2,000)
Total stockholders’ equity
  4,430 
  5,085 
 
 $46,825 
 $50,376 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 
 
3
 
  
Vaso Corporation and Subsidiaries
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(unaudited)
(in thousands, except per share data)
 
 
 
 
Three months ended
 
 
 
March 31,
 
 
 
2021
 
 
2020
 
Revenues
 
 
 
 
 
 
Managed IT systems and services
 $11,253 
 $11,283 
Professional sales services
  4,655 
  5,166 
Equipment sales and services
  611 
  778 
Total revenues
  16,519 
  17,227 
 
    
    
Cost of revenues
    
    
Cost of managed IT systems and services
  6,847 
  6,811 
Cost of professional sales services
  990 
  1,020 
Cost of equipment sales and services
  123 
  257 
Total cost of revenues
  7,960 
  8,088 
Gross profit
  8,559 
  9,139 
 
    
    
Operating expenses
    
    
Selling, general and administrative
  8,954 
  10,319 
Research and development
  144 
  180 
Total operating expenses
  9,098 
  10,499 
Operating loss
  (539)
  (1,360)
 
    
    
Other (expense) income
    
    
Interest and financing costs
  (135)
  (261)
Interest and other income, net
  49 
  27 
Total other (expense) income, net
  (86)
  (234)
 
    
    
Loss before income taxes
  (625)
  (1,594)
Income tax benefit (expense)
  (18)
  119 
Net loss
  (643)
  (1,475)
 
    
    
Other comprehensive loss
    
    
Foreign currency translation loss
  (21)
  (65)
Comprehensive loss
 $(664)
 $(1,540)
 
    
    
Loss per common share
    
    
- basic and diluted
 $(0.00)
 $(0.01)
 
    
    
Weighted average common shares outstanding
    
    
- basic and diluted
  170,836 
  168,936 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 
 
4
 
 
Vaso Corporation and Subsidiaries
 
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands)
 
 
 
     
 
 
     
 
 
 
 
 
 
 
 
Accumulated
 
 
 
 
 
 
     
 
 
     
 
 
 
 
 
 
 
 
Other
 
 
Total
 
 
 
Common Stock  
 
 
Treasury Stock  
 
 
Additional
 
 
Accumulated
 
 
Comprehensive
 
 
 Stockholders’
 
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
Paid-in-Capital
 
 
Deficit
 
 
 Loss
 
 
Equity
 
Balance at January 1, 2020
  183,744 
 $184 
  (10,308)
  (2,000)
 $63,803 
 $(57,360)
 $(313)
 $4,314 
Share-based compensation
  1,000 
  1 
  - 
  - 
  26 
  - 
  - 
  27 
Foreign currency translation loss
  - 
  - 
  - 
  - 
  - 
  - 
  (65)
  (65)
Net loss
  - 
  - 
  - 
  - 
  - 
  (1,475)
  - 
  (1,475)
Balance at March 31, 2020 (unaudited)
  184,744 
 $185 
  (10,308)
 $(2,000)
 $63,829 
 $(58,835)
 $(378)
 $2,801 
 
    
    
    
    
    
    
    
    
Balance at January 1, 2021
  185,244 
 $185 
  (10,308)
  (2,000)
 $63,886 
 $(57,002)
 $16 
 $5,085 
Share-based compensation
  - 
  - 
  - 
  - 
  9 
  - 
  - 
  9 
Foreign currency translation loss
  - 
  - 
  - 
  - 
  - 
  - 
  (21)
  (21)
Net loss
  - 
  - 
  - 
  - 
  - 
  (643)
  - 
  (643)
Balance at March 31, 2021 (unaudited)
  185,244 
 $185 
  (10,308)
 $(2,000)
 $63,895 
 $(57,645)
 $(5)
 $4,430 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 
 
5
 
 
Vaso Corporation and Subsidiaries
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
 
 
 
Three months ended  
 
 
 
March 31,  
 
 
 
2021
 
 
2020
 
Cash flows from operating activities
 
 
 
 
 
 
Net loss
 $(643)
 $(1,475)
Adjustments to reconcile net loss to net
    
    
  cash provided by operating activities
    
    
Depreciation and amortization
  596 
  623 
Deferred income taxes
  - 
  (124)
Gain from investment in EECP Global
  (13)
  - 
Provision for doubtful accounts and commission adjustments
  263 
  79 
Share-based compensation
  9 
  27 
Changes in operating assets and liabilities:
    
    
Accounts and other receivables
  4,979 
  9,160 
Inventories
  234 
  (65)
Deferred commission expense
  (157)
  632 
Prepaid expenses and other current assets
  86 
  (328)
Other assets, net
  171 
  (676)
Accounts payable
  (171)
  33 
Accrued commissions
  (1,124)
  (1,156)
Accrued expenses and other liabilities
  720 
  191 
Sales tax payable
  (77)
  (38)
Deferred revenue
  781 
  (667)
Due to related party
  (128)
  (15)
Other long-term liabilities
  (51)
  142 
Net cash provided by operating activities
  5,475 
  6,343 
 
    
    
Cash flows from investing activities
    
    
Purchases of equipment and software
  (59)
  (172)
Net cash used in investing activities
  (59)
  (172)
 
    
    
Cash flows from financing activities
    
    
Net (repayment) borrowings on revolving lines of credit
  (1,525)
  (100)
Repayment of notes payable and finance lease obligations
  (1,276)
  (340)
Repayment of notes payable - related parties
  - 
  (323)
Net cash used in financing activities
  (2,801)
  (763)
Effect of exchange rate differences on cash and cash equivalents
  (2)
  26 
 
    
    
NET INCREASE IN CASH AND CASH EQUIVALENTS
  2,613 
  5,434 
Cash and cash equivalents - beginning of period
  6,819 
  2,124 
Cash and cash equivalents - end of period
 $9,432 
 $7,558 
 
    
    
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
    
    
Interest paid
 $168 
 $173 
Income taxes paid
 $16 
 $- 
 
    
    
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
    
    
Initial recognition of operating lease right of use asset and liability
 $131 
 $- 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 
 
6
Vaso Corporation and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS
 
Vaso Corporation was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.
 
Overview
 
Vaso Corporation principally operates in three distinct business segments in the healthcare and information technology (“IT”) industries. We manage and evaluate our operations, and report our financial results, through these three business segments.
 
IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;
 
Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for General Electric Healthcare (“GEHC”) into the healthcare provider middle market; and
 
Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software.
 
VasoTechnology
 
VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). It currently consists of a managed network and security service division and a healthcare IT application VAR (value added reseller) division. Its current offerings include:
 
Managed radiology and imaging applications (channel partner of select vendors of healthcare IT products).
Managed network infrastructure (routers, switches and other core equipment).
Managed network transport (FCC licensed carrier reselling over 175 facility partners).
Managed security services.
 
VasoTechnology uses a combination of proprietary technology, methodology and third-party applications to deliver its value proposition.
 
VasoHealthcare
 
VasoHealthcare commenced operations in 2010, in conjunction with the Company’s execution of its exclusive sales representation agreement (“GEHC Agreement”) with GEHC, which is the healthcare business division of the General Electric Company ("GE"), to further the sale of certain healthcare capital equipment in the healthcare provider middle market. Sales of GEHC equipment by the Company have grown significantly since then.
 
VasoHealthcare’s current offerings consist of:
 
GEHC diagnostic imaging capital equipment.
GEHC service agreements for the above equipment.
GEHC training services for use of the above equipment.
GEHC and third party financial services.
 
 
7
 
 
VasoMedical
 
VasoMedical is the Company’s business division for its proprietary medical device operations, including the design, development, manufacturing, sales and service of various medical devices in the domestic and international markets and includes the Vasomedical Global and Vasomedical Solutions business units (see Note M). These devices are primarily for cardiovascular monitoring and diagnostic systems. Its current offerings consist of:
 
Biox™ series Holter monitors and ambulatory blood pressure recorders.
ARCS® series analysis, reporting and communication software for ECG and blood pressure signals.
MobiCare™ multi-parameter wireless vital-sign monitoring system.
EECP® therapy systems for non-invasive, outpatient treatment of ischemic heart disease.
 
This segment uses its extensive cardiovascular device knowledge coupled with its significant engineering resources to cost-effectively create and market its proprietary technology. It works with a global distribution network of channel partners to sell its products. It also provides engineering and OEM services to other medical device companies.
 
NOTE B – INTERIM STATEMENT PRESENTATION
 
Basis of Presentation and Use of Estimates
 
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial information. Certain information and disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on May 5, 2021.
 
These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.
 
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.
 
Significant Accounting Policies and Recent Accounting Pronouncements
 
Recently Adopted Accounting Pronouncements
 
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides new guidance regarding the measurement and recognition of credit impairment for certain financial assets. Such guidance will impact how we determine our allowance for estimated uncollectible receivables. In November 2019, the FASB issued ASU 2019-10, which changed the effective date of ASU 2016-13 for smaller reporting companies as defined by the SEC from first quarter of 2020 to the first quarter of 2023, with early adoption permitted. We are currently evaluating the effect that ASU 2016-13 will have on our consolidated financial statements and related disclosures.
 
Prior Periods’ Financial Statement Revisions
 
As disclosed in our 2020 Annual Report, we identified certain misstatements in our previously issued financial statements. The misstatements included misappropriation of funds by a mid-level management employee and partially recording certain regulatory fees billed to our customers as revenue. We assessed the materiality of the misstatements on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Materiality, codified in Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, (“ASC 250”) and concluded that the misstatements were not material to the prior annual or interim periods. However, in our 2020 Annual Report, we revised our previously issued 2019 consolidated financial statements to correct for these misstatements.
 
In connection with the filing of this Quarterly Report, we have revised the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), Cash Flows, and Changes in Stockholders’ Equity for the three months ended March 31, 2020, and the related notes to revise for those misstatements that impacted such period. We will revise the remaining previously issued 2020 quarterly financial statements in connection with corresponding 2021 quarterly filings on Form 10-Q in the future.
 
 
8
 
 
 
 
Consolidated Statement of Operations and
Comprehensive Income (Loss)
 
 
 
Three months ended March 31, 2020 (unaudited)
 
 (in thousands, except per share data)
 
As Reported
 
 
Adjustment
 
 
As Revised
 
Revenues
 
 
 
 
 
 
 
 
 
Managed IT systems and services
 $11,339 
 $(56)
 $11,283 
 
    
    
    
Gross Profit - IT segment
  4,528 
  (56)
  4,472 
 
    
    
    
Operating expenses
    
    
    
Selling, general and administrative
  10,267 
  52 
  10,319 
Operating loss
 $(1,252)
 $(108)
 $(1,360)
 
    
    
    
Net loss
 $(1,367)
 $(108)
 $(1,475)
 
    
    
    
Comprehensive loss
 $(1,432)
 $(108)
 $(1,540)
 
    
    
    
Loss per common share
    
    
    
- basic and diluted
 $(0.01)
 $(0.00)
 $(0.01)
 
 
 
Consolidated Statement of Cash Flows
 
 
 
Three months ended March 31, 2020 (unaudited)
 
 (in thousands)
 
As Reported
 
 
Adjustment
 
 
As Revised
 
Net loss
 $(1,367)
 $(108)
 $(1,475)
Accounts payable
 $(75)
 $108 
 $33 
 
 
 
Consolidated Statement of Changes in Stockholders' Equity
 
 
 
Accumulated Deficit
 
 
Total Shareholders' Equity
 
 (in thousands)
 
As Reported
 
 
Adjustment
 
 
As Revised
 
 
As Reported
 
 
Adjustment
 
 
As Revised
 
Balance at January 1, 2020
 $(55,885)
 $(1,475)
 $(57,360)
 $5,789 
 $(1,475)
 $4,314 
 
    
    
    
    
    
    
Net loss
 $(1,367)
 $(108)
 $(1,475)
 $(1,367)
 $(108)
 $(1,475)
 
    
    
    
    
    
    
Balance at March 31, 2020 (unaudited)
 $(57,252)
 $(1,583)
 $(58,835)
 $4,384 
 $(1,583)
 $2,801 
 
 
9
 
 
NOTE C – REVENUE RECOGNITION
 
Disaggregation of Revenue
 
The following tables present revenues disaggregated by our business operations and timing of revenue recognition:
 
 
 
(in thousands)
 
 
 
      Three Months Ended March 31, 2021     
 
 
      Three Months Ended March 31, 2020     
 
 
 
IT segment
 
 
Professional sales
service segment
 
 
Equipment segment
 
 
Total
 
 
IT segment
 
 
Professional sales
service segment
 
 
Equipment segment
 
 
Total
 
Network services
 $10,118 
 
 
 
 
 
 
 $10,118 
 $10,376 
 
 
 
 
 
 
 $10,376 
Software sales and support
  1,135 
 
 
 
 
 
 
  1,135 
  907 
 
 
 
 
 
 
  907 
Commissions
    
  4,655 
 
 
 
  4,655 
    
  5,166 
 
 
 
  5,166 
Medical equipment sales
    
    
  577 
  577 
    
    
  571 
  571 
Medical equipment service
    
    
  34 
  34 
    
    
  207 
  207 
 
 $11,253 
 $4,655 
 $611 
 $16,519 
 $11,283 
 $5,166 
 $778 
 $17,227 
   
 
 
Three Months Ended March 31, 2021
 
 
Three Months Ended March 31, 2020
 
 
 
IT segment
 
 
Professional sales service segment
 
 
Equipment segment
 
 
Total
 
 
IT segment
 
 
Professional sales service segment
 
 
Equipment segment
 
 
Total
 
Revenue recognized over time
 $10,025 
 $- 
 $30 
 $10,055 
 $10,494 
 $- 
 $140 
 $10,634 
Revenue recognized at a point in time
  1,228 
  4,655 
  581 
  6,464 
  789 
  5,166 
  638 
  6,593 
 
 $11,253 
 $4,655 
 $611 
 $16,519 
 $11,283 
 $5,166 
 $778 
 $17,227 
 
Transaction Price Allocated to Remaining Performance Obligations
 
As of March 31, 2021, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $68.8 million, of which we expect to recognize revenue as follows:
     
 
 
(in thousands)
 
 
 
Fiscal years of revenue recognition (unaudited)
 
 
 
remainder of 2021
 
 
2022
 
 
2023
 
 
Thereafter
 
Unfulfilled performance obligations
 $31,641 
 $19,846 
 $7,418 
 $9,942 
 
Contract Liabilities
 
Contract liabilities arise in our IT VAR, VasoHealthcare, and VasoMedical businesses. In our IT VAR business, payment arrangements with clients typically include an initial payment due upon contract signing and milestone-based payments based upon product delivery and go-live, as well as post go-live monthly payments for subscription and support fees. Customer payments received, or receivables recorded, in advance of go-live and customer acceptance, where applicable, are deferred as contract liabilities. Such amounts aggregated approximately $415,000 and $553,000 at March 31, 2021 and December 31, 2020, respectively, and are included in accrued expenses and other liabilities in our condensed consolidated balance sheets.
 
In our VasoHealthcare business, we bill amounts for certain milestones in advance of customer acceptance of the underlying equipment. Such amounts aggregated approximately $18,472,000 and $17,689,000 at March 31, 2021 and December 31, 2020, respectively, and are classified in our condensed consolidated balance sheets as either current or long-term deferred revenue. In addition, we record a contract liability for amounts expected to be repaid to GEHC due to customer order reductions. Such amounts aggregated approximately $865,000 and $1,118,000 at March 31, 2021 and December 31, 2020, respectively, and are included in accrued expenses and other liabilities in our condensed consolidated balance sheets.
 
 
10
 
 
In our VasoMedical business, we bill amounts for post-delivery services and varying duration service contracts in advance of performance. Such amounts aggregated approximately $13,000 and $15,000 at March 31, 2021 and December 31, 2020, respectively, and are classified in our condensed consolidated balance sheets as either current or long-term deferred revenue.
 
During the three March 31, 2021, we recognized approximately $1.7 million of revenues that were included in our contract liability balance at January 1, 2021.
 
NOTE D – SEGMENT REPORTING AND CONCENTRATIONS
 
Vaso Corporation principally operates in three distinct business segments in the healthcare and information technology industries. We manage and evaluate our operations, and report our financial results, through these three reportable segments.
 
IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;
 
Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GEHC into the healthcare provider middle market; and
 
Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., primarily focuses on the design, manufacture, sale and service of proprietary medical devices.
 
The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income and adjusted EBITDA (net income (loss), plus interest expense (income), net; tax expense; depreciation and amortization; and non-cash stock-based compensation). Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:
 
 
 
11
Vaso Corporation and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 
       
 
 
(in thousands)
 
 
 
Three Months ended March 31,
 
 
 
2021
 
 
2020
 
 
 
(unaudited)
 
 
(unaudited)
 
Revenues from external customers
 
 
 
 
 
 
IT
 $11,253 
 $11,283 
Professional sales service
  4,655 
  5,166 
Equipment
  611 
  778 
Total revenues
 $16,519 
 $17,227 
 
    
    
Gross Profit
    
    
IT
 $4,406 
 $4,472 
Professional sales service
  3,665 
  4,146 
Equipment
  488 
  521 
Total gross profit
 $8,559 
 $9,139 
 
    
    
Operating income (loss)
    
    
IT
 $69 
 $(593)
Professional sales service
  (336)
  (434)
Equipment
  13 
  (48)
Corporate
  (285)
  (285)
Total operating income (loss)
 $(539)
 $(1,360)
 
    
    
Depreciation and amortization
    
    
IT
 $486 
 $507 
Professional sales service
  38 
  41 
Equipment
  72 
  75 
Corporate
  - 
  - 
Total depreciation and amortization
 $596 
 $623 
 
    
    
Capital expenditures
    
    
IT
 $24 
 $157 
Professional sales service
  - 
  - 
Equipment
  35 
  13 
Corporate
  - 
  2 
Total cash capital expenditures
 $59 
 $172 
 
 
12
 
 
 
 
(in thousands)
 
 
 
March 31,
2021
 
 
December 31,
2020
 
 
 
(unaudited)
 
 
 
 
Identifiable Assets
 
 
 
 
 
 
IT
 $27,537 
 $28,110 
Professional sales service
  5,274 
  9,171 
Equipment
  6,501 
  6,668 
Corporate
  7,513 
  6,427 
Total assets
 $46,825 
 $50,376 
 
GE Healthcare accounted for 28% and 30% of revenue for the three months ended March 31, 2021 and 2020, respectively. GE Healthcare also accounted for $0.7 million or 15%, and $5.1 million or 52%, of accounts and other receivables at March 31, 2021 and December 31, 2020, respectively.
 
NOTE E –LOSS PER COMMON SHARE
 
Basic loss per common share is computed as loss applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.
 
The following table represents common stock equivalents that were excluded from the computation of diluted loss per share for the three months ended March 31, 2021 and 2020, because the effect of their inclusion would be anti-dilutive.
 
 
 
(in thousands)
 
 
 
Three months ended March 31,  
 
 
 
2021
 
 
2020
 
 
 
(unaudited)
 
 
(unaudited)
 
Restricted common stock grants
  3,691 
  6,420 
 
NOTE F – ACCOUNTS AND OTHER RECEIVABLES, NET
 
The following table presents information regarding the Company’s accounts and other receivables as of March 31, 2021 and December 31, 2020:
 
 
 
(in thousands)
 
 
 
March 31,
2021
 
 
December 31,
2020
 
 
 
(unaudited)
 
 
 
 
Trade receivables
 $8,694 
 $13,960 
Unbilled receivables
  348 
  - 
Due from employees
  - 
  24 
Allowance for doubtful accounts and
    
    
commission adjustments
  (4,510)
  (4,208)
Accounts and other receivables, net
 $4,532 
 $9,776 
 
 
13
 
 
Contract receivables under Topic 606 consist of trade receivables and unbilled receivables. Trade receivables include amounts due for shipped products and services rendered. Unbilled receivables represent variable consideration recognized in accordance with Topic 606 but not yet billable. Amounts recorded – billed and unbilled - under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.
 
Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees is primarily commission advances made to sales personnel.
 
NOTE G – INVENTORIES, NET
 
Inventories, net of reserves, consist of the following:                     
 
 
 
      (in thousands)
 
 
 
March 31,
2021
 
 
December 31,
2020
 
 
 
(unaudited)
 
 
 
 
Raw materials
 $648 
 $669 
Work in process
  35 
  4 
Finished goods
  464 
  711 
 
 $1,147 
 $1,384 
 
 
The Company maintained reserves for slow moving inventories of $167,000 at both March 31, 2021 and December 31, 2020.
 
NOTE H – GOODWILL AND OTHER INTANGIBLES
 
Goodwill of $14,375,000 is allocated to the IT segment. The remaining $1,308,000 of goodwill is attributable to the FGE reporting unit within the Equipment segment. The NetWolves and FGE reporting units had negative net asset carrying amounts at March 31, 2021 and December 31, 2020. The components of the change in goodwill are as follows:
 
 
 
      (in thousands)
 
 
 
Three months ended
 
 
Year ended
 
 
 
March 31,
2021
 
 
December 31,
2020
 
 
 
(unaudited)
 
 
 
 
Beginning of period
 $15,688 
 $17,271 
Foreign currency translation adjustment
  (5)
  82 
Sale of equity in EECP Global
  - 
  (1,665)
End of period
 $15,683 
 $15,688 
 
 
14
 
 
The Company’s other intangible assets consist of capitalized customer-related intangibles, patent and technology costs, and software costs, as set forth in the following:
 
 
 
      (in thousands)
 
 
 
March 31,
2021
 
 
December 31,
2020
 
 
 
(unaudited)
 
 
 
 
Customer-related
 
 
 
 
 
 
Costs
 $5,831 
 $5,831 
Accumulated amortization
  (4,030)
  (3,947)
 
  1,801 
  1,884 
 
    
    
Patents and Technology
    
    
Costs
  1,894 
  1,894 
Accumulated amortization
  (1,579)
  (1,521)
 
  315 
  373 
 
    
    
Software
    
    
Costs
  3,422 
  3,394 
Accumulated amortization
  (1,775)
  (1,702)
 
  1,647 
  1,692 
 
    
    
 
 $3,763 
 $3,949 
 
Patents and technology are amortized on a straight-line basis over their estimated useful lives of ten and eight years, respectively. The cost of significant customer-related intangibles is amortized in proportion to estimated total related revenue; cost of other customer-related intangible assets is amortized on a straight-line basis over the asset's estimated economic life of seven years. Software costs are amortized on a straight-line basis over its expected useful life of five years.
 
Amortization expense amounted to $214,000 and $232,000 for the three months ended March 31, 2021 and 2020, respectively.
 
Amortization of intangibles for the next five years is:
 
 
 
(in thousands)  
 
Years ending December 31,
 
(unaudited)
 
Remainder of 2021
  816 
2022
  787 
2023
  562 
2024
  493 
2025
  426 
 
 $3,084 
 
 
15
 
 
NOTE I – OTHER ASSETS, NET
 
Other assets, net consist of the following at March 31, 2021 and December 31, 2020:
 
 
 
      (in thousands)
 
 
 
March 31,
2021
 
 
December 31,
2020
 
 
 
(unaudited)
 
 
 
 
Deferred commission expense - noncurrent
 $1,572 
 $1,683 
Trade receivables - noncurrent
  357 
  448 
Other, net of allowance for loss on loan receivable of
    
    
  $412 at March 31, 2021 and December 31, 2020
  81 
  59 
 
 $2,010 
 $2,190 
 
NOTE J – ACCRUED EXPENSES AND OTHER LIABILITIES
 
Accrued expenses and other liabilities consist of the following at March 31, 2021 and December 31, 2020:
 
 
 
      (in thousands)
 
 
 
March 31,
2021
 
 
December 31,
2020
 
 
 
(unaudited)
 
 
 
 
Accrued compensation
 $845 
 $1,044 
Accrued expenses - other
  1,380 
  1,854 
Other liabilities
  3,593 
  1,969 
 
 $5,818 
 $4,867 
 
 
16
Vaso Corporation and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 
 
NOTE K - DEFERRED REVENUE
 
The changes in the Company’s deferred revenues are as follows:
 
 
 
      (in thousands)
 
 
 
  Three months ended March 31,  
 
 
 
2021
 
 
2020
 
 
 
(unaudited)
 
 
(unaudited)
 
Deferred revenue at beginning of period
 $17,704 
 $19,343 
Net additions:
    
    
Deferred extended service contracts
  (1)
  142 
Deferred in-service and training
  - 
  3 
Deferred service arrangements
  - 
  5 
Deferred commission revenues
  2,614 
  1,404 
Recognized as revenue:
    
    
Deferred extended service contracts
  (1)
  (136)
Deferred in-service and training
  - 
  - 
Deferred service arrangements
  - 
  (5)
Deferred commission revenues
  (1,832)
  (2,081)
Deferred revenue at end of period
  18,484 
  18,675 
Less: current portion
  12,387 
  9,701 
Long-term deferred revenue at end of period
 $6,097 
 $8,974 
 
NOTE L – NOTES PAYABLE
 
Notes payable consist of the following:
 
 
 
      (in thousands)
 
 
 
March 31, 2021
 
 
December 31, 2020
 
 
 
(unaudited)
 
 
 
 
Line of credit
 $2,821 
 $4,346 
Notes payable
  3,801 
  3,803 
Notes payable - MedTech
  2,400 
  3,600 
Total debt
  9,022 
  11,749 
Less: current portion
  (3,972)
  (5,970)
 
 $5,050 
 $5,779 
 
 
17
 
 
NetWolves maintains a $4.0 million line of credit with a lending institution. In March 2021, the line’s expiration date was extended to June 30, 2022 provided $825,000 was paid prior to April 1, 2021, and $50,000 is paid quarterly beginning June 30, 2021. Advances under the line are secured by substantially all of the assets of NetWolves Network Services, LLC and guaranteed by Vaso Corporation. During the quarter ended March 31, 2021, $850,000 in draw was repaid. At March 31, 2021, the Company had drawn approximately $2.8 million against the line, of which amount $200,000 is included in notes payable – current portion in the Company’s condensed consolidated balance sheet at March 31, 2021. No additional borrowing is permitted under the line. The credit agreement includes certain financial covenants. The Company was in compliance with such covenants at March 31, 2021.
 
The Company maintained an additional $2.0 million line of credit with a lending institution. In March 2021, the $675,000 balance and accrued interest was paid off in full and the line was closed.
 
In April 2020, the Company’s Biox subsidiary issued a note RMB1,000,000 (approximately $147,000) with a Chinese bank for working capital purposes. The note is secured by the assets of Biox and bears interest at 4.35%. It matured on April 15, 2021 and was repaid in full.
 
Paycheck Protection Program debt
 
In April 2020, the Company received funding of a $3,610,900 Note (the “PPP Note”) issued by PNC Bank, National Association (“PNC”) pursuant to the Coronavirus Aid, Relief, and Economic Security (CARES) Act’s Paycheck Protection Program (the “Program”).
 
The Company accounts for the PPP Note in accordance with Financial Accounting Standards Board ASC Topic 470, Debt, and Technical Question and Answer (TQA) 3200.18, Borrower Accounting for a Forgivable Loan Received Under the Small Business Administration Paycheck Protection Program. Under the TQA, the Company:
 
Initially records the cash inflow from the PPP loan as a financial liability and accrues interest in accordance with the interest method under ASC Subtopic 835-30.
 
Does not impute additional interest at a market rate.
 
Continues to record the proceeds from the loan as a liability until either (i) the loan is partly or wholly forgiven and the debtor has been legally released or (ii) the debtor pays off the loan.
 
Reduces the liability by the amount forgiven and records a gain on extinguishment once the loan is partly or wholly forgiven and legal release is received.
 
Amounts outstanding on the PPP Note are at the annual interest rate of 1%. During the first six months of the PPP Note, there is no principal nor interest required to be paid. Thereafter, to the extent the PPP Note is not forgiven under the Program, the outstanding balance of the PPP Note converts to an amortizing term loan payable monthly over an eighteen-month period, which has been updated according to the Paycheck Protection Program Flexibility Act of 2020 (“Flexibility Act”). The PPP Note can be prepaid at any time without penalty.
 
In June 2020, the Flexibility Act was signed into law, which amended the CARES Act. The Flexibility Act changed key provisions of the PPP, including, but not limited to, (i) provisions relating to the maturity of PPP loans, (ii) the deferral period covering of PPP loan payments and (iii) the process for measurement of loan forgiveness. More specifically, the Flexibility Act provides a minimum maturity of five years for all PPP loans made on or after the date of the enactment of the Flexibility Act (“June 5, 2020”) and permits lenders and borrowers to extend the maturity date of earlier PPP loans by mutual agreement. As of the date of this filing, the Company has not approached the lender to request an extension of the maturity date from two years to five years. The Flexibility Act also provides that if a borrower does not apply for forgiveness of a loan within 10 months after the last day of the measurement period (“covered period”), the PPP loan is no longer deferred and the borrower must begin paying principal and interest. In addition, the Flexibility Act extended the length of the covered period from eight weeks to 24 weeks from receipt of proceeds, while allowing borrowers that received PPP loans before June 5, 2020 to determine, at their sole discretion, a covered period of either 8 weeks or 24 weeks.
 
After reviewing the applicable terms and conditions of the Flexibility Act, the Company elected to extend the length of the covered period from the lesser of (i) period whereby qualified expenses equal loan proceeds or (ii) 24 weeks. The Company has performed initial calculations for the PPP loan forgiveness according to the terms and conditions of the SBA’s Loan Forgiveness Application (Revised June 16, 2020) and, based on such calculations, expects that the PPP loan will be forgiven in full over a period less than 24 weeks. In October 2020, the Company submitted its application to PNC for forgiveness of the PPP Note in an amount equal to the sum of the following costs incurred by the Company during the covered period beginning on the date of first disbursement of the PPP Note proceeds:
 
(a) payroll costs;
(b) any payment of interest on a covered mortgage obligation;
(c) any covered rent payment; and
(d) any covered utility payment.
 
The amount of forgiveness is calculated in accordance with the requirements of the Program. In this regard, no more than 40% of the amount forgiven can be attributable to non-payroll costs.
 
 
18
 
 
NOTE M – RELATED-PARTY TRANSACTIONS
 
The Company recorded interest charges aggregating approximately $54,000 and $121,000 for the three-month periods ended March 31, 2021 and 2020, respectively, payable to MedTechnology Investments, LLC (“MedTech”) pursuant to its promissory notes (“Notes”). The MedTech Notes were used in 2015 to partially fund the purchase of NetWolves. $2,300,000 of the $4,800,000 provided by MedTech was provided by directors of the Company, or by their family members. The Notes bore interest, payable quarterly, at an annual rate of 9% through their original maturity date of May 29, 2019. In August 2018, MedTech agreed to extend the maturity date of $3,600,000 of the Notes an additional year from May 29, 2019 to May 29, 2020, provided that a minimum of $1,200,000 of the principal was paid on or before December 31, 2019 and the annual interest rate for the balance increased to 10% during the extension. The $1,200,000 principal payment was waived pursuant to MedTech’s consent to the bank line of credit maturity extension to September 30, 2020. The Notes may be prepaid without penalty, and are subordinated to any current or future Senior Debt as defined in the Subordinated Security Agreement. The Subordinated Security Agreement secures payment and performance of the Company’s obligations under the Notes. In April 2020, $1.2 million in principal was repaid and the maturity date of $3.6 million of the Notes were extended through April 30, 2021 at a new interest rate of 6% per annum. The maturity date was extended again in March 2021 to June 30, 2022, provided $1.2 million was paid prior to April 1, 2021, and $50,000 is paid quarterly beginning June 30, 2021. The interest rate remains at 6% per annum. $1.2 million in principal and $54,000 in accrued interest was paid on March 31, 2021. $200,000 of the $2.4 million outstanding balance of the MedTech Notes is included in current liabilities in the Company’s condensed consolidated balance sheet as of March 31, 2021
 
David Lieberman, the Vice Chairman of the Company’s Board of Directors, is a practicing attorney in the State of New York and a senior partner at the law firm of Beckman Lieberman & Associates LLP, which performs certain legal services for the Company. Fees of approximately $47,000 and $63,000 were billed by the firm for the three-month periods ended March 31, 2021 and 2020, respectively, at which times no amounts were outstanding.
 
In April, 2020, the Company closed on the sale of 51% of the capital stock of its wholly-owned subsidiary EECP Global Corporation (“EECP Global”) to Chongqing PSK-Health Sci-Tech Development Co. Ltd, a China-based company, for $1,150,000. EECP Global was formed to in September 2019 hold all the assets and liabilities of its EECP business. Concurrently with the closing of the transaction, the Company signed a three-year Management Service Agreement with EECP Global to provide management service for the business and operation of EECP Global in the United States. Pursuant to the agreement, EECP Global reimburses the Company all direct expenses and pays a management fee starting April 1, 2020, the effective date of the sale.
 
The Company uses the equity method to account for its interest in EECP Global as it has the ability to exercise significant influence over the entity and reports its share of EECP Global operations in Other Income (Expense) on its condensed consolidated statements of operations. For the three months ended March 31, 2021, the Company’s share of EECP Global’s income was approximately $13,000 and included in Other (Expense) Income in its condensed consolidated statements of operations. At March 31, 2021, the Company recorded a net payable to related parties of approximately $105,000 on its condensed consolidated balance sheet for amounts due to EECP Global for receivables collected on its behalf net of amounts due from EECP Global for fees and cost reimbursements.
 
NOTE N – COMMITMENTS AND CONTINGENCIES
 
Litigation
 
The Company is currently, and has been in the past, a party to various legal proceedings, primarily employee related matters, incident to its business. The Company believes that the outcome of all pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.
 
Sales representation agreement
 
In December 2017, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010. The amendment extended the term of the agreement through December 31, 2022, subject to earlier termination with or without cause under certain circumstances after timely notice. Under the agreement, VasoHealthcare is the exclusive representative for the sale of select GE Healthcare diagnostic imaging products to specific market segments/accounts in the 48 contiguous states of the United States and the District of Columbia. The agreement may be terminated by GE Healthcare without cause subject to certain conditions. The circumstances under which early termination of the agreement may occur with cause include: not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and not meeting various legal and GEHC policy requirements.
 
Employment Agreements
 
On May 10, 2019, the Company modified its Employment Agreement with its President and Chief Executive Officer, Dr. Jun Ma, to provide for a five-year term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond May 31, 2026. The Employment Agreement provides for annual compensation of $500,000. Dr. Ma shall be eligible to receive a bonus for each fiscal year during the employment term. The amount and the occasion for payment of such bonus, if any, shall be at the discretion of the Board of Directors. Dr. Ma shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company's stock, as determined at the Board of Directors' discretion. The Employment Agreement further provides for reimbursement of certain expenses, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.
 
 
19
Vaso Corporation and Subsidiaries
 
 
ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the current COVID-19 pandemic which has already adversely affected operating results; the effect of the dramatic changes taking place in IT and healthcare; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; continuation of the GEHC agreement and the risk factors reported from time to time in the Company’s SEC reports, including its recent report on Form 10-K. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
 
Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries
 
General Overview
 
COVID-19 pandemic
 
The COVID-19 pandemic has had and will continue to have a significant impact on the United States economy and it is anticipated that its negative impact to the Company’s financial condition and results of operations will continue. At this time we cannot reasonably estimate what the total impact may be. The pandemic has resulted in workforce and travel restrictions and created business disruptions in supply chain, production and demand across many business sectors. Equipment orders in our professional sales service segment have been negatively impacted, and we do anticipate continued negative impact in all our businesses during the remainder of 2021, in particular in our professional sales service segment for the diagnostic imaging equipment. Moreover, we have also experienced the negative impact in the recurring revenue business in our IT segment as some of our customers have been adversely affected by the shutdown, and new business in this segment appears to be slower as well. The pandemic also may have a negative impact on our cash receipts as some customers request forbearance or a delay in their payments to us.
 
The pandemic may impact our operations beyond the first quarter of 2021, depending on the duration of the pandemic and the timing and success of the reopening of the economy.
 
We have taken significant steps in our efforts to protect our workforce and our clients. Many of our employees have been working remotely and we are implementing plans to reopen our work sites consistent with the guidelines promulgated by the CDC and respective state governments. In addition, the Company received a $3.6 million loan under the Paycheck Protection Program of the CARES Act. This loan, substantially all of which shall qualify for forgiveness, has been used to principally cover our payroll costs for a period of time as specified by the rules, thereby allowing us to maintain our workforce and continue to provide services and solutions to our clients. We have applied for forgiveness of the PPP loan.
 
Our Business Segments
 
Vaso Corporation (“Vaso”) was incorporated in Delaware in July 1987. We principally operate in three distinct business segments in the healthcare and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.
 
IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;
 
Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GEHC into the healthcare provider middle market; and
 
Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., primarily focuses on the design, manufacture, sale and service of proprietary medical devices.
 
Critical Accounting Policies and Estimates
 
Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.
 
Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see Note B to the condensed consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on May 5, 2021.
 
 
20
 
 
Prior Periods’ Financial Statement Revision
 
Certain prior period amounts have been revised to reflect the impact of corrections of misstatements and to correct the timing of previously recorded out-of-period adjustments. Refer to Note B in the Notes to Condensed Consolidated Financial Statements for more information.
 
Results of Operations – For the Three Months Ended March 31, 2021 and 2020
 
Revenues
 
Total revenue for the three months ended March 31, 2021 and 2020 was $16,519,000 and $17,227,000, respectively, representing a decrease of $708,000, or 4% year-over-year. On a segment basis, revenue in the IT, professional sales service and equipment segments decreased $30,000, $511,000 and $167,000, respectively.
 
Revenue in the IT segment for the three months ended March 31, 2021 was $11,253,000 compared to $11,283,000 for the three months ended March 31, 2020, a decrease of $30,000, or less than 1%, of which $257,000 resulted from lower NetWolves revenue, partially offset by a $227,000 increase in the operations of the healthcare IT VAR business. Our monthly recurring revenue in the IT segment accounted for $10,025,000 or 89% of the segment revenue in the first quarter of 2021, and $10,494,000 or 93% of the segment revenue for the same quarter last year (see Note C).
 
Commission revenues in the professional sales service segment were $4,655,000 in the first quarter of 2021, a decrease of 10%, as compared to $5,166,000 in the same quarter of 2020. The decrease in commission revenues was due primarily to both a decrease in the volume of underlying equipment delivered by GEHC during the period and a lower blended commission rate applicable to such deliveries. The Company only recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable, or billed and received, under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet. As of March 31, 2021, $18,472,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $6,090,000 was long-term. At March 31, 2020, $17,890,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $8,625,000 was long-term. The increase in deferred revenue is principally due to an increase in new orders booked.
 
Revenue in the equipment segment decreased by $167,000, or 22%, to $611,000 for the three-month period ended March 31, 2021 from $778,000 for the same period of the prior year, principally due to the Company deconsolidating EECP operations beginning in the second quarter of 2020 as a result of the sale of equity in the EECP business. On a proforma basis with EECP operations also excluded from the financial statements for the first quarter of 2020, revenue in the equipment segment would increase by $78,000, or 16%.
 
Gross Profit
 
Gross profit for the three months ended March 31, 2021 and 2020 was $8,559,000, or 52% of revenue, and $9,139,000, or 53% of revenue, respectively, representing a decrease of $580,000, or 6% year-over-year. On a segment basis, gross profit in the IT, professional sales service, and equipment segments decreased $66,000, or 2%; $481,000, or 12%; and $33,000, or 6%, respectively.
 
IT segment gross profit for the three months ended March 31, 2021 was $4,406,000, or 39% of the segment revenue, compared to $4,472,000, or 40% of the segment revenue for the three months ended March 31, 2020. The year-over-year decrease of $66,000, or 2%, was primarily a result of lower margin product sales mix in the IT VAR business partially offset by a higher margin sales mix at NetWolves.
 
Professional sales service segment gross profit was $3,665,000, or 79% of segment revenue, for the three months ended March 31, 2021 as compared to $4,146,000, or 80% of the segment revenue, for the three months ended March 31, 2020, reflecting a decrease of $481,000, or 12%. The decrease in absolute dollars was primarily due to lower commission revenue as a result of lower blended commission rate and lower volume of GEHC equipment delivered during the first quarter of 2021 than in the same period last year. Cost of commissions in the professional sales service segment of $990,000 and $1,020,000, for the three months ended March 31, 2021 and 2020, respectively, reflected commission expense associated with recognized commission revenues.
 
Commission expense associated with short-term deferred revenue is recorded as short-term deferred commission expense, or with long-term deferred revenue as part of other assets, on the balance sheet until the related commission revenue is recognized.
 
Equipment segment gross profit decreased to $488,000, or 80% of segment revenues, for the first quarter of 2021 compared to $521,000, or 67% of segment revenues, for the same quarter of 2020. The $33,000, or 6%, decrease in gross profit was the result of lower revenue due to deconsolidation of EECP operations in the financial statements for the first quarter of 2021, partially offset by higher gross profit margin of non-EECP products sold during the quarter.
 
Operating Loss
 
Operating loss for the three months ended March 31, 2021 and 2020 was $539,000 and $1,360,000, respectively, representing an improvement of $821,000, or 60%, as operating costs (below) decreased much more than gross profit did, year-over-year. On a segment basis, IT segment recorded operating income of $69,000 in the first quarter of 2021 as opposed to an operating loss of $593,000 in the same period of 2020; equipment segment recorded operating income of $13,000 in the first quarter of 2020 as opposed to an operating loss of $48,000 in the same period of 2021; and operating loss in the professional sales service segment decreased by $98,000, from $433,000 in the first quarter of 2020 to $335,000 in the same period of 2021.
 
 
21
 
 
Operating income in the IT segment increased to $69,000 for the three-month period ended March 31, 2021 as compared to an operating loss of $593,000 in the same period of 2020, due to lower selling, general, and administrative (“SG&A”) costs partially offset by lower gross profit. Operating loss in the professional sales service segment decreased $98,000 in the three-month period ended March 31, 2021 as compared to operating loss in the same period of 2020, due to lower SG&A costs partially offset by lower gross profit. The equipment segment reported operating income of $13,000 in the first quarter of 2021, compared to an operating loss of $48,000 in the first quarter 2020, an improvement of $61,000. The improvement was due to lower SG&A and R&D costs partially offset by lower gross profit.
 
SG&A costs for the three months ended March 31, 2021 and 2020 were $8,954,000 and $10,319,000, respectively, representing a decrease of $1,365,000, or 13% year-over-year. On a segment basis, SG&A costs in the IT segment decreased by $607,000 in the first quarter of 2021 from the same quarter of the prior year due to reduced personnel costs; SG&A costs in the professional sales service segment decreased $579,000 due mainly to lower national sales meeting and travel costs; and SG&A costs in the equipment segment decreased $74,000 due mainly to lower personnel costs. Corporate costs not allocated to segments were approximately unchanged in the three months ended March 31, 2021 from the same period in 2020.
 
Research and development (“R&D”) expenses were $144,000, or 1% of revenues, for the first quarter of 2021, a decrease of $36,000, or 20%, from $180,000, or 1% of revenues, for the first quarter of 2020. The decrease is primarily attributable to lower product development expenses and a reduction in technical staff in the equipment segment.
 
Adjusted EBITDA
 
We define Adjusted EBITDA (earnings (loss) before interest, taxes, depreciation and amortization), which is a non-GAAP financial measure, as net income (loss), plus interest expense (income), net; tax expense; depreciation and amortization; and non-cash expenses for share-based compensation.  Adjusted EBITDA is a metric that is used by the investment community for comparative and valuation purposes. We disclose this metric in order to support and facilitate the dialogue with research analysts and investors.
 
Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and should not be considered a substitute for operating income, which we consider to be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with U.S. GAAP. Other companies may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
 
A reconciliation of net loss to Adjusted EBITDA is set forth below: 
 
 
 
      (in thousands)
 
 
 
Three months ended March 31,
 
 
 
2021
 
 
2020
 
 
 
(unaudited)
 
 
(unaudited)
 
Net loss
 $(643)
 $(1,475)
Interest expense (income), net
  121 
  261 
Income tax (benefit) expense
  18 
  (119)
Depreciation and amortization
  596 
  623 
Share-based compensation
  9 
  27 
Adjusted EBITDA
 $101 
 $(683)
 
Adjusted EBITDA increased by $784,000, to $101,000 in the quarter ended March 31, 2021 from $(683,000) in the quarter ended March 31, 2020. The increase was attributable to the decrease in net loss, partially offset primarily by the decrease in interest expense.
 
Interest and Other Income (Expense)
 
Interest and other income (expense) for the three months ended March 31, 2021 was $(86,000) as compared to $(234,000) for the corresponding period of 2020. The decrease in interest and other income (expense) was due primarily to lower interest expense due to principal payments against the line of credit and other notes payable and lower interest rates applicable to such notes payable.
 
Income Tax (Expense) Benefit
 
For the three months ended March 31, 2021, we recorded income tax expense of $18,000 as compared to income tax benefit of $(119,000) for the corresponding period of 2020. The change from benefit to expense arose mainly from the reversal in the first quarter of 2020 of deferred tax liability in our China operations.
 
 
22
 
 
Net Loss
 
Net loss for the three months ended March 31, 2021 was $643,000 as compared to $1,475,000 for the three months ended March 31, 2020, representing an improvement of $832,000, or 56%. Loss per share of $0.00 and $0.01 was recorded in the three-month periods ended March 31, 2021 and 2020, respectively. The principal cause of the decrease in net loss is the change from operating loss to operating income in the IT segment, an improvement of $662,000, as well as smaller improvements in the professional sales service and equipment segments. due primarily to lower SG&A costs.
 
Liquidity and Capital Resources
 
Cash and Cash Flow
 
We have financed our operations from working capital. At March 31, 2021, we had cash and cash equivalents of $9,432,000 and negative working capital of $10,373,000, compared to cash and cash equivalents of $6,819,000 and negative working capital of $9,431,000 at December 31, 2020. $9,875,000 in negative working capital at March 31, 2021 is attributable to the net balance of deferred commission expense and deferred revenue. These are non-cash expense and revenue items and have no impact on future cash flows.
 
Cash provided by operating activities was $5,475,000, which consisted of net loss after adjustments to reconcile net loss to net cash of $212,000 and cash provided by operating assets and liabilities of $5,263,000, during the three months ended March 31, 2021, compared to cash provided by operating activities of $6,343,000 for the same period in 2020. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $4,979,000, partially offset by decreases in accrued commissions and accounts payable of $1,124,000 and $171,000, respectively.
 
Cash used in investing activities during the three-month period ended March 31, 2021 was $59,000 for the purchase of equipment and software.
 
Cash used in financing activities during the three-month period ended March 31, 2021 was $2,801,000 resulting from repayments of lines of credit and notes payable.
 
Liquidity
 
The Company expects to generate sufficient cash flow from operations to satisfy its obligations for the next twelve months.
 
It is anticipated that the COVID-19 pandemic may continue to adversely impact our operations during and beyond the remaining quarters of 2021, depending on the duration of the pandemic and the timing and success of the reopening of the economy.
 
 
23
Vaso Corporation and Subsidiaries
 
 
ITEM 4 - CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures
 
Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
 
As of the end of the period covered by this report, an evaluation was performed under the supervision and with the participation of the Company’s senior management, including the Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures to provide reasonable assurance of achieving the desired objectives of the disclosure controls and procedures. In light of the material weaknesses noted in our Annual Report on Form 10-K for our fiscal year ended December 31, 2020, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2021, our disclosure controls and procedures were not effective.
 
Changes in Internal Control Over Financial Reporting
 
There were no changes in the Company’s internal control over financial reporting during the Company’s fiscal quarter ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
 
 
24
Vaso Corporation and Subsidiaries
 
 
 
PART II - OTHER INFORMATION
 
ITEM 6 – EXHIBITS
 
Exhibits
 
31 
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32 
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
25
Vaso Corporation and Subsidiaries
 
 
 
In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
VASO CORPORATION
 
 
 
 
 
Date:  June 4, 2021
By:  
/s/ Jun Ma  
 
 
 
Jun Ma
 
 
 
President and Chief Executive Officer
(Principal Executive Officer)
 
 
 
     
 
 
 
/s/ Michael J. Beecher      
 
 
 
Michael J. Beecher      
 
 
 
Chief Financial Officer and Principal Accounting Officer      
 
 
 
     
 

 
 
26
EX-31.1 2 vaso_ex311.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 vaso_ex311
 
EXHIBIT 31.1
 
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Jun Ma, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of Vaso Corporation and subsidiaries (the “registrant”);
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
 
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Jun Ma .
Jun Ma
President and Chief Executive Officer
 
Date: June 4 2021
 
 
EX-31.2 3 vaso_ex312.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 vaso_ex312
 
EXHIBIT 31.2
 
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Michael J. Beecher, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of Vaso Corporation and subsidiaries (the “registrant”);
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
 
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Michael J. Beecher .
Michael J. Beecher
Chief Financial Officer
 
Date: June 4, 2021
 
 
 
EX-32.1 4 vaso_ex321.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 vaso_ex321
 
EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the quarterly report of Vaso Corporation and subsidiaries (the “Company”) on Form 10-Q for the period ending March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jun Ma, as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
/s/ Jun Ma .
Jun Ma
President and Chief Executive Officer
 
Dated: June 4, 2021
 
 
 
 
EX-32.2 5 vaso_ex322.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 vaso_ex322
 
EXHIBIT 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the quarterly report of Vaso Corporation and subsidiaries (the “Company”) on Form 10-Q for the period ending March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Beecher, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
/s/ Michael J. Beecher .
Michael J. Beecher
Chief Financial Officer
Dated: June 4, 2021
 
 
GRAPHIC 6 vaso_10q000.jpg IMAGE begin 644 vaso_10q000.jpg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vaso-20210331.xml XBRL INSTANCE DOCUMENT 0000839087 2021-01-01 2021-03-31 0000839087 2021-03-31 0000839087 2020-01-01 2020-03-31 0000839087 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0000839087 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0000839087 us-gaap:CorporateNonSegmentMember 2021-03-31 0000839087 2019-12-31 0000839087 2020-03-31 0000839087 VASO:ServiceArrangementsMember 2021-01-01 2021-03-31 0000839087 VASO:ExtendedServiceContractsMember 2021-01-01 2021-03-31 0000839087 VASO:ServiceArrangementsMember 2020-01-01 2020-03-31 0000839087 VASO:CommissionRevenuesMember 2021-01-01 2021-03-31 0000839087 VASO:InServiceAndTrainingMember 2020-01-01 2020-03-31 0000839087 VASO:CommissionRevenuesMember 2020-01-01 2020-03-31 0000839087 VASO:ExtendedServiceContractsMember 2020-01-01 2020-03-31 0000839087 VASO:InServiceAndTrainingMember 2021-01-01 2021-03-31 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-03-31 0000839087 us-gaap:CustomerRelationshipsMember 2021-03-31 0000839087 VASO:PatentsAndTechnologyMember 2021-03-31 0000839087 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000839087 2020-01-01 2020-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000839087 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0000839087 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0000839087 VASO:CommissionsMember 2020-01-01 2020-03-31 0000839087 VASO:MedicalEquipmentSalesMember 2020-01-01 2020-03-31 0000839087 VASO:SoftwareSalesAndSupportMember 2021-01-01 2021-03-31 0000839087 VASO:NetworkServicesMember 2021-01-01 2021-03-31 0000839087 VASO:SoftwareSalesAndSupportMember 2020-01-01 2020-03-31 0000839087 VASO:MedicalEquipmentServiceMember 2021-01-01 2021-03-31 0000839087 us-gaap:TransferredOverTimeMember 2021-01-01 2021-03-31 0000839087 VASO:NetworkServicesMember 2020-01-01 2020-03-31 0000839087 VASO:CommissionsMember 2021-01-01 2021-03-31 0000839087 VASO:MedicalEquipmentSalesMember 2021-01-01 2021-03-31 0000839087 us-gaap:TransferredOverTimeMember 2020-01-01 2020-03-31 0000839087 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-03-31 0000839087 us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-03-31 0000839087 VASO:MedicalEquipmentServiceMember 2020-01-01 2020-03-31 0000839087 us-gaap:CommonStockMember 2019-12-31 0000839087 us-gaap:TreasuryStockMember 2019-12-31 0000839087 us-gaap:CommonStockMember 2021-03-31 0000839087 us-gaap:TreasuryStockMember 2021-03-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000839087 us-gaap:RetainedEarningsMember 2019-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000839087 us-gaap:RetainedEarningsMember 2021-03-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember 2021-01-01 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember 2021-01-01 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember 2021-01-01 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember 2020-01-01 2020-03-31 0000839087 VASO:ProfessionalSalesServicesMember 2020-01-01 2020-03-31 0000839087 VASO:EquipmentSalesAndServicesMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:NetworkServicesMember 2021-01-01 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:SoftwareSalesAndSupportMember 2021-01-01 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:CommissionsMember 2021-01-01 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:MedicalEquipmentSalesMember 2021-01-01 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:MedicalEquipmentServiceMember 2021-01-01 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:NetworkServicesMember 2021-01-01 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:SoftwareSalesAndSupportMember 2021-01-01 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:CommissionsMember 2021-01-01 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:MedicalEquipmentSalesMember 2021-01-01 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:MedicalEquipmentServiceMember 2021-01-01 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:NetworkServicesMember 2021-01-01 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:SoftwareSalesAndSupportMember 2021-01-01 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:CommissionsMember 2021-01-01 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:MedicalEquipmentSalesMember 2021-01-01 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:MedicalEquipmentServiceMember 2021-01-01 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:NetworkServicesMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:SoftwareSalesAndSupportMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:CommissionsMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:MedicalEquipmentSalesMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember VASO:MedicalEquipmentServiceMember 2020-01-01 2020-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:NetworkServicesMember 2020-01-01 2020-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:SoftwareSalesAndSupportMember 2020-01-01 2020-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:CommissionsMember 2020-01-01 2020-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:MedicalEquipmentSalesMember 2020-01-01 2020-03-31 0000839087 VASO:ProfessionalSalesServicesMember VASO:MedicalEquipmentServiceMember 2020-01-01 2020-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:NetworkServicesMember 2020-01-01 2020-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:SoftwareSalesAndSupportMember 2020-01-01 2020-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:CommissionsMember 2020-01-01 2020-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:MedicalEquipmentSalesMember 2020-01-01 2020-03-31 0000839087 VASO:EquipmentSalesAndServicesMember VASO:MedicalEquipmentServiceMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-03-31 0000839087 VASO:ProfessionalSalesServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-03-31 0000839087 VASO:ProfessionalSalesServicesMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-03-31 0000839087 VASO:EquipmentSalesAndServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-03-31 0000839087 VASO:EquipmentSalesAndServicesMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember 2021-01-01 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember 2021-01-01 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember 2021-01-01 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember 2020-01-01 2020-03-31 0000839087 VASO:ProfessionalSalesServicesMember 2020-01-01 2020-03-31 0000839087 VASO:EquipmentSalesAndServicesMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember 2021-03-31 0000839087 VASO:ProfessionalSalesServicesMember 2021-03-31 0000839087 VASO:EquipmentSalesAndServicesMember 2021-03-31 0000839087 VASO:GeHealthcareMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-03-31 0000839087 VASO:GeHealthcareMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-03-31 0000839087 VASO:GeHealthcareMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0000839087 VASO:GeHealthcareMember us-gaap:AccountsReceivableMember 2021-01-01 2021-03-31 0000839087 VASO:GeHealthcareMember us-gaap:AccountsReceivableMember 2021-03-31 0000839087 VASO:ThereafterMember 2021-03-31 0000839087 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000839087 us-gaap:CommonStockMember 2020-03-31 0000839087 us-gaap:TreasuryStockMember 2020-03-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000839087 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000839087 us-gaap:RetainedEarningsMember 2020-03-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000839087 us-gaap:CommonStockMember 2020-12-31 0000839087 us-gaap:TreasuryStockMember 2020-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000839087 us-gaap:RetainedEarningsMember 2020-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000839087 2020-12-31 0000839087 VASO:Year2022Member 2021-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember 2020-12-31 0000839087 VASO:ProfessionalSalesServicesMember 2020-12-31 0000839087 VASO:EquipmentSalesAndServicesMember 2020-12-31 0000839087 us-gaap:CorporateNonSegmentMember 2020-12-31 0000839087 VASO:GeHealthcareMember us-gaap:AccountsReceivableMember 2020-12-31 0000839087 us-gaap:CustomerRelationshipsMember 2020-12-31 0000839087 VASO:PatentsAndTechnologyMember 2020-12-31 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-12-31 0000839087 VASO:RemainderOf2021Member 2021-03-31 0000839087 VASO:Year2023Member 2021-03-31 0000839087 2021-06-02 0000839087 VASO:ManagedITSystemsAndServicesMember srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-03-31 0000839087 VASO:ManagedITSystemsAndServicesMember srt:RestatementAdjustmentMember 2020-01-01 2020-03-31 0000839087 srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-03-31 0000839087 srt:RestatementAdjustmentMember 2020-01-01 2020-03-31 0000839087 srt:ScenarioPreviouslyReportedMember 2020-03-31 0000839087 srt:RestatementAdjustmentMember 2020-03-31 0000839087 srt:ScenarioPreviouslyReportedMember 2019-12-31 0000839087 srt:RestatementAdjustmentMember 2019-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares VASO:Segment xbrli:pure VASO Corp 0000839087 --12-31 Yes Non-accelerated Filer false true false Yes DE 0-18105 2021 Q1 10-Q false 2021-03-31 175127878 19468000 22268000 1064000 1151000 2512000 2354000 1147000 1384000 18000 18000 4532000 700000 9776000 5100000 763000 766000 9432000 2124000 7558000 6819000 271000 271000 1129000 1116000 2010000 2190000 3763000 1647000 1801000 315000 3949000 1884000 373000 1692000 15683000 17271000 15688000 968000 1009000 3533000 3885000 46825000 7513000 27537000 5274000 6501000 50376000 28110000 9171000 6668000 6427000 29841000 31699000 108000 236000 3972000 5970000 12387000 9701000 11516000 544000 621000 602000 540000 180000 190000 2010000 2190000 116000 1474000 6114000 33000 6285000 -75000